ADAR1 Capital Management’s Dyne Therapeutics DYN Stock Holding History

ADAR1 Capital Management’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$861K	Buy	47,463 +4,789	+11%	+$82.6K	0.05%	175
2025 Q4	$835K	Buy	42,674 +5,011	+13%	+$94.9K	0.06%	147
2025 Q3	$476K	Buy	37,663 +14,600	+63%	+$167K	0.04%	140
2025 Q2	$220K	Sell	23,063 -7,036	-23%	-$77.5K	0.03%	153
2025 Q1	$315K	Buy	+30,099	New	+$431K	0.06%	128
2024 Q4	–	Sell	-400	Closed	-$14.4K	–	240
2024 Q3	$14.4K	Buy	+400	New	+$15.9K	﹤0.01%	249
2024 Q2	–	Sell	-297	Closed	-$8.43K	–	284
2024 Q1	$8.43K	Buy	+297	New	+$6.72K	﹤0.01%	232

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

ADAR1 Capital Management's DYN Position: Q1 2026 in Review

ADAR1 Capital Management increased its Dyne Therapeutics (DYN) stake by 11% in Q1 2026, buying an estimated $82.6K and bringing the position to 47,463 shares worth $861K. The position accounts for 0.05% of the portfolio, ranked #175.

ADAR1 Capital Management first reported a position in DYN in Q1 2024 and has held it in 7 quarters since. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

ADAR1 Capital Management held 47,463 shares of Dyne Therapeutics worth $861K as of Q1 2026.
ADAR1 Capital Management bought 4,789 Dyne Therapeutics shares in Q1 2026, an estimated $82.6K.
Dyne Therapeutics made up 0.05% of ADAR1 Capital Management's portfolio in Q1 2026, its #175 holding.
ADAR1 Capital Management first reported a position in Dyne Therapeutics in Q1 2024 and has held it in 7 quarters since.
227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.